Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Several other research firms have also recently weighed in on CYCC. Roth Mkm increased their price objective on shares of Cyclacel Pharmaceuticals from $16.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, December 19th. Brookline Capital Management cut shares of Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th.

Cyclacel Pharmaceuticals Stock Performance

Shares of NASDAQ CYCC opened at $1.58 on Tuesday. Cyclacel Pharmaceuticals has a 52-week low of $1.57 and a 52-week high of $13.20. The firm has a 50 day moving average price of $2.39 and a two-hundred day moving average price of $4.02. The stock has a market cap of $2.09 million, a P/E ratio of -0.06 and a beta of 0.54.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.35) by $0.12. The business had revenue of $0.03 million during the quarter. Analysts predict that Cyclacel Pharmaceuticals will post -18.7 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Schonfeld Strategic Advisors LLC lifted its position in shares of Cyclacel Pharmaceuticals by 25.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 770,400 shares of the biotechnology company’s stock valued at $514,000 after purchasing an additional 155,200 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Cyclacel Pharmaceuticals by 166.0% during the third quarter. Renaissance Technologies LLC now owns 167,600 shares of the biotechnology company’s stock valued at $245,000 after purchasing an additional 104,600 shares in the last quarter. Millennium Management LLC lifted its position in shares of Cyclacel Pharmaceuticals by 6.5% during the fourth quarter. Millennium Management LLC now owns 208,062 shares of the biotechnology company’s stock valued at $139,000 after purchasing an additional 12,617 shares in the last quarter. Two Sigma Investments LP bought a new position in shares of Cyclacel Pharmaceuticals during the third quarter valued at about $98,000. Finally, Virtu Financial LLC bought a new position in shares of Cyclacel Pharmaceuticals during the second quarter valued at about $33,000. 23.58% of the stock is owned by institutional investors.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.